2023, Number 10
<< Back Next >>
Ginecol Obstet Mex 2023; 91 (10)
Essential thrombocytosis of pregnancy onset. Case report and literature review
Haro GLM, Pérez RFR
Language: Spanish
References: 11
Page: 788-797
PDF size: 228.45 Kb.
ABSTRACT
Background: The coexistence of myeloproliferative neoplasms during pregnancy
may lead to maternal and fetal complications, and early detection is essential.
Clinical case: A 30-year-old primigravida. Prenatal examination revealed a significant
increase in platelets and leukocytes. After exclusion of an infectious process and
consultation with the haematologist, she was prescribed an antiplatelet agent. The
pregnancy proceeded without thrombotic or haemorrhagic complications and was
terminated by caesarean section at 40 weeks, indicated for lack of progress in labour.
Specific treatment of the disease and follow-up were then initiated.
Methodology: Articles published in the last 20 years were searched in PubMed
and Clinical Key databases using MeSH "essential thrombocythemia AND pregnancy",
"haematological neoplasms AND pregnancy".
Results: We obtained 14 articles, of which 3 were excluded because they did not
include pregnant women. The final review consisted of 11 articles.
Conclusions: Correct follow-up of antenatal care can warn of medical complications
independent of pregnancy. In this case, timely intervention and involvement of
other specialists is possible to confirm the diagnosis and make the best joint decision
for the benefit of the mother and her unborn child.
REFERENCES
Harrison CN, Robinson SE. Myeloproliferative Disordersin Pregnancy. Hematol Oncol Clin North Am 2011; 25 (2): 261-75. https://doi.org/10.1016/j.hoc.2011.01.008
Skeith L, Carrier M, Robinson SE, Alimam S, Rodger MA.Risk of venous thromboembolism in pregnant womenwith essential thrombocythemia: a systematic review andmeta-analysis. Blood 2017; 129 (8): 934-39. https://doi.org/10.1182/blood-2016-09-728006
Gangat N, Tefferi A. Myeloproliferative neoplasms andpregnancy: Overview and practice recommendations. AmJ Hematol 2021; 96 (3): 354-66. https://pubmed.ncbi.nlm.nih.gov/33296529/
Guglielmelli P, Vannucchi AM. Current managementstrategies for polycythemia vera and essential thrombocythemia.Blood Reviews 2020; 42: 100714. https://doi.org/10.1016/j.blre.2020.100714
Puyade M, Cayssials E, Pierre F, Pourrat O. Pregnancy andmyeloproliferative neoplasms: A retrospective monocentriccohort. Obstet Med 2017; 10 (4): 165. https://doi.org/10.1177/1753495x17708896
How J, Leiva O, Bogue T, Fell GG, Bustoros MW, ConnellNT, et al. Pregnancy outcomes, risk factors, and cellcount trends in pregnant women with essential thrombocythemia.Leuk Res 2020; 98: 106-459. https://doi.org/10.1016/j.leukres.2020.106459
Burbury K, Panigrahi A. Esssential thrombocythaemia andpregnancy—A need for prospective study and a consensuson its management. Leuk Res 2021; 102: 1-3. https://doi.org/10.1016/j.leukres.2021.106500
İskender D, Yılmaz-Ergani S, Aksoy M, Tokgoz B, IbanogluMC, Kızıl Çakar M, et al. High rate of obstetric complicationsin patients with essential thrombocythemia. Cureus 2021;13 (12): e20449. doi:10.7759/cureus.20
Umazume T, Yamada T, Akaishi R, Araki N, Nishida R, MorikawaM, et al. Essential thrombocythemia as a risk factorfor stillbirth. Thromb Res 2014; 133 (2): 158-61. https://doi.org/10.1016/j.thromres.2013.11.004
Belčič Mikič T, Vratanar B, Pajič T, Anžej Doma S, DebeljakN, Preložnik Zupan I, et al. Is it possible to predict clonalthrombocytosis in triple-negative patients with isolatedthrombocytosis based only on clinical or blood findings?J Clin Med 2021; 10 (24): 5803. https://doi.org/10.3390/jcm10245803
Valera MC, Parant O, Vayssiere C, Arnal JF, Payrastre B.Essential thrombocythemia and pregnancy. European JObstet Gynecol Reprod Biol 2011; 158 (2): 141-7. https://doi.org/10.1016/j.ejogrb.2011.04.040
Full text